Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Antiviral Activity
100%
Remdesivir
100%
SARS-CoV-2 Variants
100%
GS-441524
100%
IC50 Value
50%
COVID-19
33%
Nsp12
33%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
33%
Variants of Interest
33%
Virus
16%
Nucleoprotein
16%
RNA-dependent RNA Polymerase (RdRP)
16%
FDA-approved Drugs
16%
Publicly Available
16%
Disease Severity
16%
Viral Transmission
16%
Enzyme-linked Immunosorbent Assay (ELISA)
16%
Prodrug
16%
Genetic Variation
16%
Vaccine Effectiveness
16%
Nucleoside Analogues
16%
Neutralizing Antibodies
16%
Nucleosides
16%
Antiviral Treatment
16%
Recombinant Virus
16%
Plaque Reduction Assay
16%
Disease Transmission
16%
Continued Use
16%
Vaccine Antibodies
16%
Rapid Spread
16%
Inhibitory Concentration 50
16%
Delta Variant
16%
Multiple Variants
16%
Omicron Variant
16%
P323L
16%
SARS-CoV-2 Antiviral
16%
Activity Assessment
16%
Biochemistry, Genetics and Molecular Biology
SARS Coronavirus
100%
Antiviral Activity
100%
Omicron
100%
EC50
57%
Nucleoprotein
14%
Nucleoside
14%
Enzyme
14%
Genetic Variation
14%
RNA-dependent RNA Polymerase
14%
Virus Transmission
14%
Genetic Divergence
14%
Neutralizing Antibody
14%
Virus Recombinant
14%
Nucleoside Analog
14%
Virus
14%
Immunology and Microbiology
Antiviral Activity
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Omicron Coronavirus Variant
100%
EC50
57%
COVID-19
28%
Nucleoprotein
14%
Virus Transmission
14%
RNA-dependent RNA Polymerase
14%
Genetic Variation
14%
Neutralizing Antibody
14%
Enzyme-Linked Immunosorbent Assay
14%
Recombinant Virus
14%
Virus
14%